RegenLab USA holds ribbon cutting at Brooklyn site

Brooklyn, NY RegenLab USA held a ribbon cutting ceremony to mark the opening of its new research and manufacturing facility at BioBAT at the Brooklyn Army Terminal.

Joining to welcome RegenLab USA to the borough were a host of prominent civic and business leaders including Susan Rosenthal, senior vice president of life sciences & healthcare at New York City Economic Development Corp. (NYCEDC); Dr. Eva Cramer, president at BioBAT and vice president for biotechnology & scientific affairs at SUNY Downstate Medical Center; and Randy Peers, president and CEO of the Brooklyn Chamber of Commerce.

The Switzerland-based company specializes in cellular therapy and tissue engineering medical devices including platelet-rich plasmas and bone marrow cells, and its major foreign investment in the area will create up to 150 jobs. Between operations, research, design and manufacturing positions, jobs at the site on average pay $110,000 per year and will contribute to the area’s arrival as a biotech hub. RegenLab USA’s new facility occupies 15,000 s/f.

“Our search for a manufacturing base in the United States was relatively quick as Brooklyn immediately stood out as an ideal home,” said Antoine Turzi, EO of RegenLab USA.

“We are excited to create jobs and establish ourselves in the American market right here in Brooklyn, a booming hub of bio and life sciences companies anchored by a skilled workforce and vibrant culture. We are grateful to Dr. Cramer, New York City Economic Development Corp (NYCEDC) President Rachel Loeb, and Randy Peers at the Brooklyn Chamber of Commerce for welcoming us to Brooklyn and putting into place tools that will facilitate success for RegenLab USA.”

The Brooklyn Chamber of Commerce and RegenLab USA will be hosting a life sciences symposium in May 2022 to discuss clinical advances in cell therapies and highlight the unique features of BioBAT that make it an attractive option for companies looking to grow in the field.